Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

340 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study (BMT CTN 2101).
Hill JA, Martens MJ, Young JH, Bhavsar K, Kou J, Chen M, Lee LW, Baluch A, Dhodapkar MV, Nakamura R, Peyton K, Howard DS, Ibrahim U, Shahid Z, Armistead P, Westervelt P, McCarty J, McGuirk J, Hamadani M, DeWolf S, Hosszu K, Sharon E, Spahn A, Toor AA, Waldvogel S, Greenberger LM, Auletta JJ, Horowitz MM, Riches ML, Perales MA. Hill JA, et al. Among authors: sharon e. medRxiv [Preprint]. 2024 Jan 25:2024.01.24.24301058. doi: 10.1101/2024.01.24.24301058. medRxiv. 2024. PMID: 38343800 Free PMC article. Preprint.
SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study.
Hill JA, Martens MJ, Young JH, Bhavsar K, Kou J, Chen M, Lee LW, Baluch A, Dhodapkar MV, Nakamura R, Peyton K, Howard DS, Ibrahim U, Shahid Z, Armistead P, Westervelt P, McCarty J, McGuirk J, Hamadani M, DeWolf S, Hosszu K, Sharon E, Spahn A, Toor AA, Waldvogel S, Greenberger LM, Auletta JJ, Horowitz MM, Riches ML, Perales MA. Hill JA, et al. Among authors: sharon e. Clin Infect Dis. 2024 May 27:ciae291. doi: 10.1093/cid/ciae291. Online ahead of print. Clin Infect Dis. 2024. PMID: 38801746
Exacerbation of CMV and Nontuberculous Mycobacterial Infections Following PD-1 Blockade for HIV-Associated Kaposi Sarcoma.
Anidi IU, Sakai S, Brooks K, Fling SP, Wagner MJ, Lurain K, Lindestam Arlehamn CS, Sette A, Knox KS, Brenchley JM, Uldrick TS, Sharon E, Barber DL. Anidi IU, et al. Among authors: sharon e. Open Forum Infect Dis. 2024 Mar 31;11(5):ofae183. doi: 10.1093/ofid/ofae183. eCollection 2024 May. Open Forum Infect Dis. 2024. PMID: 38680611 Free PMC article. Clinical Trial.
Bortezomib Inhibits Open Configurations of the 20S Proteasome.
Henderson LW, Gautam AKS, Sharon EM, Johnson CR, Rommel NG, Anthony AJ, Russell DH, Jarrold MF, Matouschek A, Clemmer DE. Henderson LW, et al. Among authors: sharon em. J Am Soc Mass Spectrom. 2024 May 15. doi: 10.1021/jasms.4c00080. Online ahead of print. J Am Soc Mass Spectrom. 2024. PMID: 38748611
Perspective: The COVID-19 Pandemic: Closing Borders, Opening Doors, and Breaking Ground on the Potential for Clinical Trial Access in Developing Countries Like Trinidad and Tobago.
Alleyne-Mike K, Glod J, Cuffie E, Kissoon R, Bedaysie B, Sylvester P, Boron M, Brockman JM, Moore N, Chen AP, Sharon E. Alleyne-Mike K, et al. Among authors: sharon e. JCO Glob Oncol. 2024 May;10:e2400050. doi: 10.1200/GO.24.00050. JCO Glob Oncol. 2024. PMID: 38696741 No abstract available.
Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes.
Nassar AH, El Zarif T, Khalid AB, Rahme S, Zhong C, Kwak L, Salame M, Farhat EB, Freeman D, El-Am E, Ravishankar A, Ahmad B, Nana FA, Kaldas D, Naqash AR, Sharon E, LeBoeuf NR, Cortellini A, Malgeri A, Gupta S, Al-Hader A, Sparks JA, Linnoila J, Hamnvik OR, Mouhieddine TH, Marron T, Parikh K, McKay RR, Dilling T, Choueiri TK, Adib E, Najem E, Kim SY, Sonpavde G. Nassar AH, et al. Among authors: sharon e. J Immunother Cancer. 2024 Mar 5;12(3):e008724. doi: 10.1136/jitc-2023-008724. J Immunother Cancer. 2024. PMID: 38448038 Free PMC article.
Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J.
Connolly RM, Wang V, Hyman DM, Grivas P, Mitchell EP, Wright JJ, Sharon E, Gray RJ, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Wang J, Wisinski KB, Tricoli JV, Conley BA, Harris LN, Arteaga CL, O'Dwyer PJ, Chen AP, Flaherty KT. Connolly RM, et al. Among authors: sharon e. Clin Cancer Res. 2024 Apr 1;30(7):1273-1280. doi: 10.1158/1078-0432.CCR-23-0633. Clin Cancer Res. 2024. PMID: 38433347 Clinical Trial.
340 results